Logo image of DCTH

DELCATH SYSTEMS INC (DCTH) Stock Fundamental Analysis

NASDAQ:DCTH - Nasdaq - US24661P8077 - Common Stock - Currency: USD

16.21  -0.85 (-4.98%)

After market: 16.21 0 (0%)

Fundamental Rating

5

DCTH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. DCTH has a great financial health rating, but its profitability evaluates not so good. DCTH shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DCTH has reported negative net income.
DCTH had a negative operating cash flow in the past year.
DCTH had negative earnings in each of the past 5 years.
In the past 5 years DCTH always reported negative operating cash flow.
DCTH Yearly Net Income VS EBIT VS OCF VS FCFDCTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

DCTH has a Return On Assets of -34.45%. This is comparable to the rest of the industry: DCTH outperforms 41.49% of its industry peers.
DCTH has a Return On Equity of -38.38%. This is comparable to the rest of the industry: DCTH outperforms 53.72% of its industry peers.
Industry RankSector Rank
ROA -34.45%
ROE -38.38%
ROIC N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DCTH Yearly ROA, ROE, ROICDCTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

Looking at the Gross Margin, with a value of 83.37%, DCTH belongs to the top of the industry, outperforming 94.68% of the companies in the same industry.
DCTH's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DCTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
DCTH Yearly Profit, Operating, Gross MarginsDCTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

8

2. Health

2.1 Basic Checks

DCTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
DCTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DCTH has more shares outstanding
DCTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DCTH Yearly Shares OutstandingDCTH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DCTH Yearly Total Debt VS Total AssetsDCTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

DCTH has an Altman-Z score of 36.75. This indicates that DCTH is financially healthy and has little risk of bankruptcy at the moment.
DCTH has a Altman-Z score of 36.75. This is amongst the best in the industry. DCTH outperforms 98.94% of its industry peers.
DCTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 36.75
ROIC/WACCN/A
WACC9.2%
DCTH Yearly LT Debt VS Equity VS FCFDCTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

DCTH has a Current Ratio of 12.01. This indicates that DCTH is financially healthy and has no problem in meeting its short term obligations.
DCTH's Current ratio of 12.01 is amongst the best of the industry. DCTH outperforms 95.21% of its industry peers.
A Quick Ratio of 10.88 indicates that DCTH has no problem at all paying its short term obligations.
The Quick ratio of DCTH (10.88) is better than 94.68% of its industry peers.
Industry RankSector Rank
Current Ratio 12.01
Quick Ratio 10.88
DCTH Yearly Current Assets VS Current LiabilitesDCTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.75% over the past year.
Looking at the last year, DCTH shows a very strong growth in Revenue. The Revenue has grown by 1701.69%.
The Revenue has been growing by 88.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)81.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
Revenue 1Y (TTM)1701.69%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%530.26%

3.2 Future

DCTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.69% yearly.
The Revenue is expected to grow by 42.79% on average over the next years. This is a very strong growth
EPS Next Y108.95%
EPS Next 2Y58.37%
EPS Next 3Y45.73%
EPS Next 5Y28.69%
Revenue Next Year145.46%
Revenue Next 2Y91.44%
Revenue Next 3Y62.29%
Revenue Next 5Y42.79%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DCTH Yearly Revenue VS EstimatesDCTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
DCTH Yearly EPS VS EstimatesDCTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200M -400M -600M -800M -1B

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

DCTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 32.54, DCTH can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DCTH indicates a somewhat cheap valuation: DCTH is cheaper than 68.09% of the companies listed in the same industry.
DCTH is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 32.54
DCTH Price Earnings VS Forward Price EarningsDCTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCTH Per share dataDCTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DCTH's earnings are expected to grow with 45.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.37%
EPS Next 3Y45.73%

More info and screens

0

5. Dividend

5.1 Amount

DCTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DELCATH SYSTEMS INC

NASDAQ:DCTH (5/30/2025, 4:04:10 PM)

After market: 16.21 0 (0%)

16.21

-0.85 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners39%
Inst Owner Change6.88%
Ins Owners2.88%
Ins Owner Change0%
Market Cap564.59M
Analysts85
Price Target22.95 (41.58%)
Short Float %3.19%
Short Ratio2.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-179.46%
Min EPS beat(2)-488.34%
Max EPS beat(2)129.41%
EPS beat(4)2
Avg EPS beat(4)-95.85%
Min EPS beat(4)-488.34%
Max EPS beat(4)129.41%
EPS beat(8)3
Avg EPS beat(8)-65.24%
EPS beat(12)4
Avg EPS beat(12)-48.17%
EPS beat(16)7
Avg EPS beat(16)-33.16%
Revenue beat(2)2
Avg Revenue beat(2)6.2%
Min Revenue beat(2)4.98%
Max Revenue beat(2)7.43%
Revenue beat(4)4
Avg Revenue beat(4)24.71%
Min Revenue beat(4)4.98%
Max Revenue beat(4)45.68%
Revenue beat(8)4
Avg Revenue beat(8)0.93%
Revenue beat(12)7
Avg Revenue beat(12)8.33%
Revenue beat(16)9
Avg Revenue beat(16)23.68%
PT rev (1m)0%
PT rev (3m)3.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)125%
EPS NY rev (1m)26.47%
EPS NY rev (3m)158.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)5.55%
Revenue NY rev (3m)13.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.54
P/S 15.18
P/FCF N/A
P/OCF N/A
P/B 8.21
P/tB 8.21
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)0.5
Fwd EY3.07%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS1.07
BVpS1.97
TBVpS1.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.45%
ROE -38.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.37%
FCFM N/A
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
F-Score6
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 417.16%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.01
Quick Ratio 10.88
Altman-Z 36.75
F-Score6
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)208.01%
Cap/Depr(5y)235.23%
Cap/Sales(3y)4.01%
Cap/Sales(5y)12.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.67%
EPS Next Y108.95%
EPS Next 2Y58.37%
EPS Next 3Y45.73%
EPS Next 5Y28.69%
Revenue 1Y (TTM)1701.69%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%530.26%
Revenue Next Year145.46%
Revenue Next 2Y91.44%
Revenue Next 3Y62.29%
Revenue Next 5Y42.79%
EBIT growth 1Y67.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year258.8%
EBIT Next 3Y78.7%
EBIT Next 5YN/A
FCF growth 1Y38.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.22%
OCF growth 3YN/A
OCF growth 5YN/A